Engineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine.

PD-L1/2-null human iPSC-derived dendritic cells dressed with tumor MHC complexes activate potent anti-tumor T cell responses, demonstrating a scalable vaccine platform.

• Why it matters: Current autologous dendritic cell vaccines face challenges in production and antigen diversity, limiting their therapeutic potential. Developing a universal, off-the-shelf solution could overcome these barriers and improve cancer immunotherapy.
• What they did: Researchers differentiated MHC-deficient human iPSCs into migratory dendritic cells, then "dressed" them with tumor membrane-derived MHC-antigen complexes, creating personalized yet scalable cancer vaccines. They tested the immune activation in vitro and in vivo.
• The result: PD-L1/2-null TumorDressed DCs strongly primed T cells to kill primary hematologic and solid tumors, supporting their use as an effective, adaptable, and off-the-shelf cancer vaccine platform.